Insider · CIK 0001725721
AH Bio Fund II, L.P.
Files at EQRX (EQRx, Inc.), SCTX (Scribe Therapeutics, Inc.). First filing Jul 29, 2026, latest Jul 29, 2026.
In brief
AH Bio Fund II, L.P. files SEC Form 4 as 10% owner at SCTX (Scribe Therapeutics, Inc.), and also at EQRX (EQRx, Inc.). Since Jul 29, 2026, AH Bio Fund II, L.P. has reported 1 open-market buy worth $5.0M and 0 open-market sells worth $0, the latest filed on Jul 29, 2026.
A track record needs three past buys with six months of prices behind them; AH Bio Fund II, L.P. has 0, so none is measured yet.
The newest scored trade: bought $5.0M of SCTX on Jul 27, 2026, filed Jul 29, 2026, scored 50 (moderate). In the last 12 months: 1 buy worth $5.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SCTX: Scribe Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Scribe Therapeutics, Inc. | $5.0M 333,333 shares | +16% | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | SCTX Scribe Therapeutics, Inc. | CConversion Common Stockindirect: By AH Bio Fund II, L.P. | +2,051,742 | - | - | 2,051,742 | Jul 29, 2026 |
| Jul 27, 2026 | SCTX Scribe Therapeutics, Inc. | CConversion Common Stockindirect: By AH Bio Fund III, L.P. | +697,650 | - | - | 697,650 | Jul 29, 2026 |
| Jul 27, 2026 | SCTX Scribe Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By AH Bio Fund II, L.P. | +333,333 | $15.00 | $5.0M | 2,385,075 | Jul 29, 2026 |
| Jul 27, 2026 | SCTX Scribe Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: By AH Bio Fund II, L.P. | -12,150,003 | $0.00 | $0 | 0 | Jul 29, 2026 |
| Jul 27, 2026 | SCTX Scribe Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: By AH Bio Fund III, L.P. | -4,131,344 | $0.00 | $0 | 0 | Jul 29, 2026 |
Questions about AH Bio Fund II, L.P.
Answered from the filings on this page, as of the latest one.
Is AH Bio Fund II, L.P. buying or selling?
In the last 12 months AH Bio Fund II, L.P. reported 1 open-market buy worth $5.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5.0M of SCTX on Jul 27, 2026. Grants, option exercises and tax withholding are not counted.
How did AH Bio Fund II, L.P.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and AH Bio Fund II, L.P. has 0.
Where does AH Bio Fund II, L.P. file Form 4?
AH Bio Fund II, L.P. has filed Form 4 at SCTX (Scribe Therapeutics, Inc.); EQRX (EQRx, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.